NAMS
NewAmsterdam Pharma Co N.V.
$34.83
-0.34 (-0.97%)
At close · Jul 2
Market Cap
$4.07B
Shares
116,903,979
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.83
Open$35.27
Day$33.87–36.34
52W$18.08–42.21
Avg vol 30d1.2M
Short int9.2M · 7.8% float · 7.3d
Short vol36%
Last earningsMay 7, 2026
DataFeb 2021–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+4% above
+
Price vs 50-day avg
+6% above
◦
RSI (14)
61 · neutral
+
MACD trend
positive
◦
52-week position
69% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $33 › 200d $34 — 200d above 50d
−
Institutional flow
3 of 171 funds reported for Jun 30 · net -187 sh shares
−
Insider flow
Net -$2.3M over 90 days · 100% sells
−
Short interest
7.85% of float · ▲ +13.2% MoM · 7.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
171 holders — mid 3-yr range
Fundamentals
Strong
−
Revenue growth
−51% Y/Y
+
EPS growth
+33% Y/Y
+
Balance sheet
net cash $490.0M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+4% above
Bullish
Price vs 50-day avg
+6% above
Bullish
RSI (14)
61 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
69% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $33 › 200d $34 — 200d above 50d
Institutional flow
Distributing
3 of 171 funds reported for Jun 30 · net -187 sh shares
Insider flow
Distributing
Net -$2.3M over 90 days · 100% sells
Short interest
Rising
7.85% of float · ▲ +13.2% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
171 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $18
Now $35 · 69%
52-wk high $42
vs 200-day avg +4%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $728.9M | FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NAMS
this stock
NewAmsterdam Pharma Co N.V.
|
$4.07B | -0.7% | -50.6% | — | 7.8% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NAMS | +9.8% | +8.5% | -2.7% | +2.8% | -0.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +8.3% | +9.7% | -10.7% | +3.0% | -9.9% |